Despite these limitations, this study fills the knowledge gap regarding the role of NLRP3 in NPC progression, suggesting that TMEM71, possibly through the NLRP3 pathway, could become a novel therapeutic target. The gene discussed is NLRP3; the disease is nasopharyngeal carcinoma.